Table 2.
Positive tests for SARS-CoV-2 infection after the first and second doses in people with a history of COVID-19 vaccination.
| First author | Country | Type of vaccines | Type of study | Group of study | SARS-COV 2 incidence | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Partial vaccinated | Unvaccinated | Rate ratio* | Full vaccinated | Unvaccinated | Rate ratio* | |||||||||
| Cases | Pearson day | Cases | Pearson day | Cases | Pearson day | Cases | Pearson day | |||||||
| Hall V. FFPH (34) | UK | BNT162b2 mRNA | Prospective cohort study | Healthcare workers. | 71 | 20,641 | 977 | 2,683 | 0.006 | 9 | 1,607 | 977 | 2,683 | 0.009 |
| Iván Martínez-Baz (52) | Spain | BNT162b2 mRNA | Prospective cohort study | Aged ≥18 years | 90 | 310 | 6,980 | 19,580 | 0.738 | 61 | 491 | 6,980 | 19,580 | 0.256 |
| T. Pilishvili (53) | USA | BNT162b2 mRNA | Case–control study | Healthcare workers | 122 | 1,472 | 707 | 3,420 | 0.347 | 149 | 1,472 | 882 | 3,420 | 0.324 |
| Ping Ye, DNP (54) | USA | BNT162b2 mRNA | Retrospective cohort | Nursing home residents | 68 | 86 | 5 | 5 | 0 | 5 | 17 | 5 | 5 | 0 |
| Tamara Pilishvili (55) | USA | BNT162b2 mRNA | Case–control study | Health care workers | 214 | 926 | 340 | 642 | 0.267 | - | - | - | - | - |
| Iván Martínez-Baz (56) | Spain | BNT162b2 mRNA | Prospective cohort study | Aged ≥18 year | 351 | 2,022 | 4,811 | 14,348 | 0.416 | 1070 | 7,972 | 4,811 | 14,348 | 0.307 |
| Sara Carazo (57) | Canada | BNT162b2 mRNA | Case–control study | Healthcare workers | 2130 | 26,719 | 6,323 | 24,986 | 0.256 | 68 | 2,022 | 6,323 | 24,986 | 0.103 |
| Carmen Cabezas (42) | Catalonia | BNT162b2 mRNA | Prospective cohort study | Healthcare workers | 1607 | 1,02,161 | 4,440 | 1,16,417 | 0.403 | - | - | - | - | - |
| Galia Zacay (44) | Israel | BNT162b2 mRNA | Retrospective cohort | Aged ≥16 years | 59 | 1,445 | 382 | 6,286 | 0.658 | 16 | 2,941 | 382 | 6,286 | 0.085 |
| Tariq Azamgarhi (58) | UK | BNT162b2 mRNA | Prospective cohort study | Healthcare workers | 23 | 1,408 | 26 | 825 | 0.51 | - | - | - | - | - |
| Jamie Lopez Bernal (59) | UK | BNT162b2 mRNA | Case–control study | Age ≥70 years, | 448 | 1,956 | 15,287 | 36,668 | 0.416 | - | - | - | - | - |
| Jamie Lopez Bernal (60) | UK | BNT162b2 mRNA | Case–control study | Aged ≥16 years, | 43 | 2,884 | 4,043 | 96,371 | 0.346 | 122 | 15,749 | 4,043 | 96,371 | 0.178 |
| T. Pilishvili (53) | USA | mRNA-1273 | Case–control study | Health care workers | 18 | 1,472 | 156 | 3,420 | 0.259 | 18 | 1,472 | 190 | 3,420 | 0.21 |
| Tamara Pilishvili (55) | USA | mRNA-1273 | Case–control study | Health care workers | 68 | 268 | 340 | 642 | 0.302 | - | - | - | - | |
| Iván Martínez-Baz (56) | Spain | mRNA-1273 | Prospective cohort | Aged ≥18 year | 70 | 517 | 4,811 | 14,348 | 0.31 | 85 | 1,127 | 4,811 | 14,348 | 0.162 |
| Sara Carazo (57) | Canada | mRNA-1273 | Case–control study | Healthcare workers | 110 | 1,639 | 6,323 | 24,986 | 0.212 | 2 | 128 | 6,323 | 24,986 | 0.047 |
| Jamie Lopez Bernal (60) | UK | mRNA-1273 | Case control | Aged ≥16 years, | 592 | 25,913 | 4,043 | 96,371 | 0.534 | 218 | 8,244 | 4,043 | 96,371 | 0.62 |
| Saurabh Bobdey (61) | India | ChAdOx1 | Prospective cohort study | - | 27 | 239 | 19 | 94 | 0.503 | 67 | 2,863 | 19 | 94 | 0.095 |
| Iván Martínez-Baz (52) | Spain | ChAdOx1 | Prospective cohort study | Aged ≥18 years | 99 | 524 | 6,980 | 19,580 | 0.42 | - | - | - | - | - |
| Iván Martínez-Baz (56) | Spain | ChAdOx1 | Prospective cohort study | Aged ≥18 year - | 302 | 1,599 | 4,811 | 14,348 | 0.462 | 272 | 1,539 | 4,811 | 14,348 | 0.426 |
| Aleena Issac (62) | India | ChAdOx1 | Prospective cohort study | Healthcare Workers | - | - | - | - | - | 16 | 243 | 35 | 80 | 0.091 |
| Jamie Lopez Bernal (59) | UK | ChAdOx1 | Case–control study | Adult age ≥70 years, | 396 | 1,342 | 15,287 | 36,668 | 0.585 | - | - | - | - | - |
| Eli S. Rosenberg (63) | USA | Combination† | Prospective cohort | Adults aged ≥18 | - | - | - | - | - | 9675 | 1,01,35,322 | 38,505 | 37,42,197 | 0.092 |
| Maria Elena Flacco (64) | Italy | Combination† | Retrospective cohort | Aged ≥18 years. | 12 | 69,539 | 6,948 | 1,75,687 | 0.004 | - | - | - | - | - |
| Aaron J. Tande (65) | USA | Combination† | Retrospective cohort | Aged ≥18 years | 42 | 3,006 | 1,436 | 45,327 | 0.433 | - | - | - | - | - |
| Anoop S. V. Shah (66) | Scotland | Combination† | Prospective cohort study | Healthcare workers | 1152 | 1,09,074 | 3,191 | 1,44,525 | 0.473 | - | - | - | - | - |
| Kristin L. Andrejko (67) | USA | Combination† | Case–control study | Aged ≥18 years | 51 | 150 | 454 | 767 | 0.355 | 20 | 106 | 454 | 767 | 0.16 |
| Nathanael Fillmore (68) | USA | Combination† | Retrospective cohort | - | - | - | - | - | - | 1546 | 3,627 | 6,326 | 11,569 | 0.616 |
| Tara C. Bouton (51) | USA | Combination† | Prospective cohort study | Healthcare workers | 96 | 7,109 | 329 | 3,481 | 0.131 | 17 | 5,913 | 329 | 3,481 | 0.028 |
| Hannah Chung (69) | Canada | Combination† | Case–control study | Aged ≥16 years | 2050 | 21,272 | 51,220 | 3,02,761 | 0.524 | 73 | 21,272 | 51,220 | 3,02,761 | 0.017 |
| Alyson Cavanaugh (70) | USA | Combination† | Case–control study | Aged ≥18 years | 17 | 56 | 179 | 463 | 0.692 | 50 | 219 | 179 | 463 | 0.469 |
*
Odds Ratio computed.
†
BNT162b2 mRNA and mRNA-1273 and ChAdOx1.